000640.KO Donga Socio Holdings
- Market cap
- KRW 594B
- P/E
- 6.9x
- P/B
- 0.49x
- ROE
- 8.3%
- Dividend yield
- 1.81%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 000640.KO undervalued?
Graham number000640.KO trades 61.1% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Donga Socio Holdings fundamental analysis
No fundamental analysis for Donga Socio Holdings yet.
Donga Socio Holdings stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Donga Socio Holdings
Dong-A Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the pharmaceutical business in South Korea. It operates through a Holding Company; Over-the-Counter Drugs and Quai-Drugs; Biosimilars and Consignment Medicines; Logistics; Packaging Solutions; and Others segments. The company develops DA-8010 in Phase 3 clinical trial to treat overactive bladder; DMB-3115, a biosimilar of Stelara in Phase 3 clinical trial; DA-1241 in Phase 2 clinical trial for the tre…
Full company profileDonga Socio Holdings financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Donga Socio Holdings annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 726B | 690B | 707B | 769B | 783B | 882B | 1.01T | 1.13T | 1.33T | 1.43T | 1.53T |
| Gross Profit | 283B | 246B | 235B | 265B | 262B | 281B | 294B | 375B | 408B | 457B | 500B |
| Operating Income | 76.0B | 53.4B | 50.2B | 52.5B | 50.6B | 61.6B | 37.9B | 76.9B | 82.1B | 97.8B | 116B |
| EBITDA | - | 82.3B | -137B | 97.7B | 235B | 137B | 103B | 163B | 195B | 178B | 131B |
| Net Income | 149B | 32.5B | -164B | 19.8B | 162B | 60.3B | 11.2B | 58.0B | 58.0B | 90.9B | 99.5B |
| EPS | - | 5,302 | -26,714 | 3,220 | 26,802 | 9,644 | 1,682 | 9,277 | 9,012 | 13,720 | 15,456 |
| Balance Sheet | |||||||||||
| Total Assets | 1.40T | 1.46T | 1.24T | 1.36T | 1.51T | 1.69T | 1.73T | 1.96T | 2.03T | 2.08T | 2.21T |
| Total Liabilities | 526B | 545B | 506B | 612B | 622B | 706B | 733B | 930B | 967B | 928B | 1.00T |
| Shareholders' Equity | 876B | 913B | 734B | 745B | 889B | 965B | 982B | 1.01T | 1.05T | 1.14T | 1.19T |
| Cash & Short-term Investments | 95.9B | 179B | 107B | 86.8B | 88.8B | 99.6B | 95.1B | 120B | 117B | 123B | 184B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 30.5B | 84.5B | 58.3B | 96.8B | 84.6B | 131B | 75.9B | 159B | 83.0B | 227B | 275B |
| Capital Expenditure | 65.0B | 25.0B | 25.1B | 44.9B | 51.9B | 70.1B | 78.6B | 160B | 75.6B | 58.6B | 89.3B |
| Free Cash Flow | - | 55.1B | 26.2B | 51.6B | 29.4B | 52.4B | -2.73B | -825M | 7.43B | 169B | 186B |
| Ratios | |||||||||||
| ROE | 17.0% | 3.6% | -22.3% | 2.7% | 18.3% | 6.2% | 1.1% | 5.7% | 5.5% | 8.0% | 8.3% |
| ROA | 10.6% | 2.2% | -13.2% | 1.5% | 10.7% | 3.6% | 0.6% | 3.0% | 2.9% | 4.4% | 4.5% |
| Net Profit Margin | 20.5% | 4.7% | -23.2% | 2.6% | 20.7% | 6.8% | 1.1% | 5.1% | 4.4% | 6.4% | 6.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Donga Socio Holdings dividends
- Dividend yield
- 1.81%
- Forward dividend
- 1,700.00 KRW
- Payout ratio
- 11.8%
- Ex-dividend date
- Jul 30, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | KRW 10.8B | 1,623 | 11.8% |
| 2024 | KRW 11.9B | 1,845 | 20.5% |
| 2023 | KRW 12.5B | 2,000 | 21.6% |
| 2022 | KRW 9.38B | 1,414 | 84.1% |
| 2021 | KRW 9.18B | 1,469 | 15.2% |
| 2020 | KRW 6.14B | 1,013 | 3.8% |
| 2019 | KRW 6.14B | 1,000 | 31.1% |
| 2018 | KRW 6.14B | 1,000 | - |
| 2017 | KRW 6.05B | 986 | 18.6% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.03:1 on Mar 11, 2026.
Who owns Donga Socio Holdings
- Insiders 46.99%
- Institutions 26.55%
- Public & others 26.46%
- Shares outstanding 6.73M
- Free float 3.07M
Donga Socio Holdings company profile
- Company name
- Donga Socio Holdings
- Ticker
- 000640.KO
- ISIN
- KR7000640003
- Exchange
- Korea Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 79
- Fiscal year end
- December
- Address
- 64, Cheonho-daero, Seoul, South Korea, 02587
- Phone
- 82 2 920 8114
- Website
- dapharm.com
About Donga Socio Holdings
Dong-A Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the pharmaceutical business in South Korea. It operates through a Holding Company; Over-the-Counter Drugs and Quai-Drugs; Biosimilars and Consignment Medicines; Logistics; Packaging Solutions; and Others segments. The company develops DA-8010 in Phase 3 clinical trial to treat overactive bladder; DMB-3115, a biosimilar of Stelara in Phase 3 clinical trial; DA-1241 in Phase 2 clinical trial for the treatment of non-alcoholic steatohepatitis; DA-1726 in Phase 1 clinical trial to treat obesity; and STP0404 for the treatment of AIDS. It also provides medical devices and equipment; healthcare solutions to customers in Bacchus, over-the-counter, consumer healthcare, and cosmetics; health functional food; contract development and manufacturing organization for biosimilar and pharmaceutical products, and oligonucleotide therapeutics; functional sports drinks under the POCARI SWEAT brand; logistics and fulfillment services; glass bottles, PET bottles, aluminum and plastic caps, and paper packaging boxes; mineral and carbonated water, and mixed drinks; and IT and construction services. In addition, the company is involved in engineering; cargo, courier, and automobile transport arrangements; transportation warehousing and leasing; real estate development; agricultural product distribution; management consulting; business management; and architectural, electrical work, fire protection, and housing contracting services. The company was formerly known as Dong-A Socio Holdings Co., Ltd. and changed its name to Dong-A Pharmaceutical Co.,Ltd. in October 2026. Dong-A Pharmaceutical Co.,Ltd. was founded in 1932 and is headquartered in Seoul, South Korea.
Donga Socio Holdings management
4- Mr. Min-Young KimCEO, President & Executive Director · born 1972
- Mr. Seung Hyun KoExecutive Director, CFO & Head of Management Support Office · born 1976
- Seong-Yeon JeongCompliance Officer · born 1982
- Mr. Dae-Woo LeeExecutive Director & Head of Management Planning · born 1973